Abigail Arroyo, Douglas R. Nordli III, Fernando Galan
<p>Fenfluramine, a serotonergic agent, was first identified in the 1980s for its potential antiseizure properties, particularly in photosensitive epilepsy and later in Dravet syndrome [<span>1</span>]. Although it was withdrawn from the market in the 1990s due to concerns over cardiovascular adverse effects, including pulmonary arterial hypertension associated with high doses, subsequent studies have demonstrated that low-dose fenfluramine can be both efficacious and well-tolerated in managing refractory epilepsies [<span>2, 3</span>].</p><p>We present a second pediatric patient with developmental and epileptic encephalopathy with spike-wave activation in sleep (DEE-SWAS) in which fenfluramine was associated with marked electroencephalographic and clinical improvements, supporting its potential role as an adjunctive therapy in this challenging epilepsy phenotype.</p><p>This 6-year-old right-handed boy with DEE-SWAS was admitted to the epilepsy monitoring unit for further evaluation. He had been experiencing seizures since age 2 years, occurring multiple times daily and lasting only a few seconds. The seizure semiology was consistent with myoclonic seizures, characterized by eyelid myoclonia and bilateral arm jerks.</p><p>Initial electroencephalography (EEG) revealed a diffusely slowed background with abundant multifocal epileptiform discharges, most prominent in the bilateral temporal regions. During wakefulness, several electroclinical seizures with eyelid myoclonia were recorded. In sleep, EEG demonstrated bilaterally synchronous spike-and-wave discharges, with a spike-wave index exceeding 85% during non–rapid eye movement (NREM) sleep.</p><p>Comprehensive genetic testing—including chromosomal microarray analysis, mitochondrial DNA analysis, and whole-exome sequencing—did not identify any pathogenic variants. Magnetic resonance imaging (MRI) of the brain was also unremarkable.</p><p>At the time of admission, the patient was receiving levetiracetam, valproic acid, clobazam, and diazepam. Despite this regimen, he exhibited significant developmental regression, particularly in motor and language skills, accompanied by severe sleep disturbances that negatively impacted his overall quality of life. Previous treatments, including high-dose intravenous methylprednisolone, intravenous immunoglobulin (IVIG), and acetazolamide, had been discontinued due to ineffectiveness or uncertain benefit.</p><p>During his epilepsy monitoring unit stay, fenfluramine was initiated at a dose of 0.2 mg/kg/day, divided into two daily administrations, as an adjunct to his ongoing antiseizure medications. In parallel, the ketogenic diet was introduced as an additional therapeutic strategy for seizure control. Within 24–48 h of initiating fenfluramine, the patient's EEG exhibited a marked improvement compared with baseline (Figure 1).</p><p>This second pediatric patient with refractory epilepsy and DEE-SWAS demonstrated significant EEG improvement following initiation of fe
{"title":"Fenfluramine's Broader Potential: A Second Notable Electroencephalogram Response in Developmental Epileptic Encephalopathy With Spike-Wave Activation in Sleep","authors":"Abigail Arroyo, Douglas R. Nordli III, Fernando Galan","doi":"10.1002/cns3.70013","DOIUrl":"https://doi.org/10.1002/cns3.70013","url":null,"abstract":"<p>Fenfluramine, a serotonergic agent, was first identified in the 1980s for its potential antiseizure properties, particularly in photosensitive epilepsy and later in Dravet syndrome [<span>1</span>]. Although it was withdrawn from the market in the 1990s due to concerns over cardiovascular adverse effects, including pulmonary arterial hypertension associated with high doses, subsequent studies have demonstrated that low-dose fenfluramine can be both efficacious and well-tolerated in managing refractory epilepsies [<span>2, 3</span>].</p><p>We present a second pediatric patient with developmental and epileptic encephalopathy with spike-wave activation in sleep (DEE-SWAS) in which fenfluramine was associated with marked electroencephalographic and clinical improvements, supporting its potential role as an adjunctive therapy in this challenging epilepsy phenotype.</p><p>This 6-year-old right-handed boy with DEE-SWAS was admitted to the epilepsy monitoring unit for further evaluation. He had been experiencing seizures since age 2 years, occurring multiple times daily and lasting only a few seconds. The seizure semiology was consistent with myoclonic seizures, characterized by eyelid myoclonia and bilateral arm jerks.</p><p>Initial electroencephalography (EEG) revealed a diffusely slowed background with abundant multifocal epileptiform discharges, most prominent in the bilateral temporal regions. During wakefulness, several electroclinical seizures with eyelid myoclonia were recorded. In sleep, EEG demonstrated bilaterally synchronous spike-and-wave discharges, with a spike-wave index exceeding 85% during non–rapid eye movement (NREM) sleep.</p><p>Comprehensive genetic testing—including chromosomal microarray analysis, mitochondrial DNA analysis, and whole-exome sequencing—did not identify any pathogenic variants. Magnetic resonance imaging (MRI) of the brain was also unremarkable.</p><p>At the time of admission, the patient was receiving levetiracetam, valproic acid, clobazam, and diazepam. Despite this regimen, he exhibited significant developmental regression, particularly in motor and language skills, accompanied by severe sleep disturbances that negatively impacted his overall quality of life. Previous treatments, including high-dose intravenous methylprednisolone, intravenous immunoglobulin (IVIG), and acetazolamide, had been discontinued due to ineffectiveness or uncertain benefit.</p><p>During his epilepsy monitoring unit stay, fenfluramine was initiated at a dose of 0.2 mg/kg/day, divided into two daily administrations, as an adjunct to his ongoing antiseizure medications. In parallel, the ketogenic diet was introduced as an additional therapeutic strategy for seizure control. Within 24–48 h of initiating fenfluramine, the patient's EEG exhibited a marked improvement compared with baseline (Figure 1).</p><p>This second pediatric patient with refractory epilepsy and DEE-SWAS demonstrated significant EEG improvement following initiation of fe","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"3 3","pages":"232-234"},"PeriodicalIF":0.0,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.70013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145101416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This previously healthy and vaccinated (except for the seasonal influenza vaccine) 12-year-old boy developed acute neurological symptoms following 3 days of fever and gastrointestinal distress. His symptoms progressed from headache and transient left-arm paresthesias to expressive aphasia, prompting emergency evaluation. He was febrile, tachycardic, and hypertensive on arrival, with fluctuating neurological deficits. Serum investigations, including blood counts, glucose, metabolic panel, urine toxicology, and anti-MOG, were normal. Influenza B was detected via nasopharyngeal swab. Magnetic resonance imaging/magnetic resonance angiography revealed confluent white matter signal changes with restricted diffusion (Figure 1) with normal vessels, consistent with an infection-triggered encephalopathy syndrome, specifically mild encephalopathy with a reversible splenial lesion (MERS) [2]. The patient's rapid clinical improvement within 24 h without treatment supported a diagnosis of influenza-associated encephalopathy (IAE), for which neuroimaging is paramount. Diffusion restriction was thought to be related to intramyelinic edema and/or inflammatory infiltrate, comparable to prior reports [1, 3]. At 3-month follow-up, he remained neurologically intact, had returned to age-appropriate schooling, and had normal repeat imaging. IAE is a rare but severe complication of influenza; the pathogenesis is not fully understood but is believed to involve dysregulated host inflammatory response to influenza, leading to varying degrees of brain dysfunction and inflammation [4, 5]. This patient with MERS with focal neurological deficits and extensive white matter involvement illustrates the variable presentation and rapid reversibility of IAE in some individuals. In contrast, more severe types of IAE require immediate neuroprotective measures in intensive care and prompt immunotherapy (namely, acute necrotizing encephalopathy) [2, 6]. Given the significant proportion of pediatric influenza-associated deaths involving IAE in the 2024-25 influenza season, prevention strategies, including seasonal influenza vaccination, remain critical [7, 8].
Andrew Silverman: conceptualization, investigation, visualization, writing – review and editing, writing – original draft. Chrisoula Cheronis: conceptualization, visualization, writing – review and editing, writing – original draft, investigation.
{"title":"Influenza-Associated Encephalopathy","authors":"Andrew Silverman, Chrisoula Cheronis","doi":"10.1002/cns3.70010","DOIUrl":"https://doi.org/10.1002/cns3.70010","url":null,"abstract":"<p>This previously healthy and vaccinated (except for the seasonal influenza vaccine) 12-year-old boy developed acute neurological symptoms following 3 days of fever and gastrointestinal distress. His symptoms progressed from headache and transient left-arm paresthesias to expressive aphasia, prompting emergency evaluation. He was febrile, tachycardic, and hypertensive on arrival, with fluctuating neurological deficits. Serum investigations, including blood counts, glucose, metabolic panel, urine toxicology, and anti-MOG, were normal. Influenza B was detected via nasopharyngeal swab. Magnetic resonance imaging/magnetic resonance angiography revealed confluent white matter signal changes with restricted diffusion (Figure 1) with normal vessels, consistent with an infection-triggered encephalopathy syndrome, specifically mild encephalopathy with a reversible splenial lesion (MERS) [<span>2</span>]. The patient's rapid clinical improvement within 24 h without treatment supported a diagnosis of influenza-associated encephalopathy (IAE), for which neuroimaging is paramount. Diffusion restriction was thought to be related to intramyelinic edema and/or inflammatory infiltrate, comparable to prior reports [<span>1, 3</span>]. At 3-month follow-up, he remained neurologically intact, had returned to age-appropriate schooling, and had normal repeat imaging. IAE is a rare but severe complication of influenza; the pathogenesis is not fully understood but is believed to involve dysregulated host inflammatory response to influenza, leading to varying degrees of brain dysfunction and inflammation [<span>4, 5</span>]. This patient with MERS with focal neurological deficits and extensive white matter involvement illustrates the variable presentation and rapid reversibility of IAE in some individuals. In contrast, more severe types of IAE require immediate neuroprotective measures in intensive care and prompt immunotherapy (namely, acute necrotizing encephalopathy) [<span>2, 6</span>]. Given the significant proportion of pediatric influenza-associated deaths involving IAE in the 2024-25 influenza season, prevention strategies, including seasonal influenza vaccination, remain critical [<span>7, 8</span>].</p><p><b>Andrew Silverman:</b> conceptualization, investigation, visualization, writing – review and editing, writing – original draft. <b>Chrisoula Cheronis:</b> conceptualization, visualization, writing – review and editing, writing – original draft, investigation.</p><p>The authors declare no conflicts of interest.</p>","PeriodicalId":72232,"journal":{"name":"Annals of the Child Neurology Society","volume":"3 3","pages":"247-248"},"PeriodicalIF":0.0,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cns3.70010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145101415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}